Biden administration recently decided to enforce Defence Production Act, which allowed it to boost vaccine production by blocking export of raw material supplies to other countries

Bharat Biotech published the interim efficacy report of phase 3 clinical trial on its COVID-19 vaccine, officially known as Covaxin. The indigenous COVID-19 vaccine is found to be 81 per cent effective in preventing the virus

Government data shows that only 10% of about 12.6 million people immunised in India have taken the COVAXIN shot, which was found to be 81% effective in an interim analysis of the late-stage trial, its developer Bharat Biotech said

Digital media norms to be administered by Centre, not states The Information and Broadcasting (I&B) Ministry on Wednesday issued memorandum to states and union territories saying that the new rules for digital news publishers and over-the-top (OTT) platforms are to be administered by the Centre, not the states. The government had notified the Information Technology (Intermediary Guidelines and Digital Media Ethics Codes) Rules, 2021 on February 25. Defence equipment sales to India sho...

Krishna Ella, Chairman of Bharat Biotech had earlier said the company is focusing on the intranasal vaccine as the existing vaccines require two-dose intramuscular injections and a country like India needs 2.6 billion syringes and needles which may add up to pollution

So far, the Pfizer-BioNTtech and Moderna vaccines, made through a novel platform technology never used in humans before, are proven to have maximum efficacy

Catch top stories from the world of business and economy with BusinessToday.In's Biz EOD report

The interim efficacy trend of 81 per cent, analysed as per the protocol approved by the Drugs Controller General of India, puts it at par with other global front-runner vaccines, stated ICMR

Data from 25,800 participants who received a vaccine or placebo in 1:1 ratio showed that the vaccine was well-tolerated; Bharat Biotech said the trial conducted with ICMR was the largest in India

Union Health Minister Dr. Harsh Vardhan has said citizens can get vaccinated according to their convenience

As senior citizens across the country take part in the vaccination drive, here is all the information they need two know about the two vaccines - Covaxin and Covishield

China has given conditional approval for a single dose COVID-19 vaccine, touted to be a rival to Johnson & Johnson's one-jab shot cleared by the US drug regulator

Drug maker Johnson & Johnson's single-shot COVID-19 vaccine is safe and effective as per the data submitted from its ongoing multi-national Phase 3 trials; Top banker Uday Kotak has welcomed the Centre's decision to lift the embargo on grant of government businesses to private banks; Amid recent surge in demand for cryptocurrencies, the Reserve Bank of India has raised concerns that the digital currency may impact financial stability in India. Watch this and more on News Blast.Also Read: RBI working on digital currency, wants to tap on blockchain technology: Das

Johnson & Johnson's single-dose COVID-19 vaccine effective, safe: FDA Drug maker Johnson & Johnson's single-shot COVID-19 vaccine is safe and effective as per the data submitted from its ongoing multi-national Phase 3 randomised, double-blind and placebo-controlled trials. This is what a  briefing document published by the US Food and Drug Administration (FDA) has said. Johnson & Johnson had sought emergency use authorisation for its vaccine on February 4. FDA's advisory co...

The real-world study involved around 1.2 million people in Israel. Pfizer vaccine has also proved to be effective against B.1.1.7 variant, also known as the UK variant of coronavirus

Biological E has tied up with vaccine maker Johnson & Johnson and Baylor College of Medicine in Houston. And, it plans to start the Phase 3 trial of the candidate licensed from Baylor College next week

The company, which has its labs in England, had in early September 2020 received the approval from the Drug Controller General (DCGI) to conduct the phase 2 clinical trial of GPP-Baladol in patients with moderate infection of the pandemic with oxygen support

As part of the review process, Dr Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 21st February 2021.

\"The interim analysis report should be out in a week,\" Bhargava said on the clinical trials against the new variants.

Coronavirus vaccine: The Covid-19 vaccine candidate of Novavax is being studied in two ongoing pivotal Phase 3 clinical trials: in the United States and Mexico, as well as in the United Kingdom